ACE inhibitors or AT-1 antagonists - Which is OPTIMAAL after acute myocardial infarction?

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 3, 2003, Pages 407-409

  Doggrell, Sheila A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acute myocardial infarction; Captopril; Losartan

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOSARTAN POTASSIUM; PLACEBO; QUINAPRIL;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIONEUROTIC EDEMA; CAUSE OF DEATH; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART DEATH; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; TASTE DISORDER;

EID: 0037350306     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.3.407     Document Type: Review

References (8)

1. DICKSTEIN K, KJEKSHUS J, OPTIMAAL STEERING COMMITTEE: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet (2002) 360:752-760.
2. UNGER T: The role of the reninangiotensin system in the development of cardiovascular disease. Am. J. Cardiol. (2002) 89(2A):3A-10A.
3. LABINJOH C, NEWBY DE, PELLEGRINI MP et al.: Potentiation of bradykinin-induced release by angiotensin-induced inhibition. J. Am. Coll. Cardiol. (2001) 38:1402-1408.
4. VAN KATS JP, DUNCKER DJ, HAITSMA DB et al.: Angiotensin-converting enzyme inhibition and angiotensin II Type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation (2000) 102:1556-1563.
5. PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N. Engl. J. Med. (1992) 327:669-677.
6. BRENNER B, COOPER M, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
7. DAHLÖF B, DEVEREUX RB, KJELDSEN S et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995-1003.
8. DOGGRELL SA: Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? Expert Opin. Pharmacother. (2002) 3(11):1543-1556.